34.56
-0.58%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bloomage Biotechnology Corp
Its shares trade on Shanghai under the ticker 688363.SS. It has been listed since 6 November 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.20bn and net income of CN¥292.1m. At that date it held total assets of CN¥8.69bn and shareholders' equity of CN¥7.09bn.
Bloomage Biotechnology Corp. Ltd. engages in the production of hyaluronic acid, sodium hyaluronate bulk drugs, and medical supplements through fermentation. The company is headquartered in Jinan, Shandong. The company went IPO on 2019-11-06. The firm's products include raw material products, medical end products, functional skin care products and functional foods. The raw material products include a series of bioactive products with hyaluronic acid as the core, which are widely used in the fields of drugs, medical devices, cosmetics, functional food and general food. The medical end products are divided into medical beauty and medicine, including ophthalmic viscoelastics, medical lubricants, soft tissue fillers, medical skin protectors and others. The functional skin care products include lotion, cream, facial mask, hand mask and others. The functional foods include hyaluronic acid water, hyaluronic acid food and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Nov 2019
- Employees
- 4,278
- Website
- bloomagebiotech.com ↗
Leadership
Pay as last reported
- Ms. Yan ZhaoChairman of the Board, General Manager, since 2019CN¥2.0m
- Mr. Hui WangChief Financial OfficerCN¥335,000
- Mr. Jiajun GuoDeputy General Manager, Director, Chief Operating Officer, since 2019CN¥925,300
- Ms. Yuan FanVice President - Business, Director, since 2022CN¥862,900
- Mr. Songyan ZouVice President - Business, Director, since 2020CN¥626,900
- Mr. Yizhen LiDeputy General Manager, Secretary of the Board, Director, since 2021CN¥1.7m
- Mr. Yi GaoDeputy General ManagerCN¥1.0m
- Mr. Aihua LiuDeputy General Manager, since 2019CN¥1.8m
- Mr. Yizheng LuanDeputy General ManagerCN¥1.0m
- Ms. Guixin XuDeputy General ManagerCN¥734,900
- Mr. Xueping GuoDirector, since 2019CN¥946,700
- Mr. Fuguo CaoIndependent DirectorCN¥150,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 91
- Environment
- 99
- Social
- 99
- Governance
- 75
- Direct emissions (scope 1)
- 37,412.27 t
- Energy emissions (scope 2)
- 76,098.72 t
- Value chain emissions (scope 3)
- 183,852.39 t
- Women in the workforce
- 48.96%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bloomage Biotechnology produces hyaluronic acid core bioactive products for drugs and cosmetics.
- Bloomage's medical end products include ophthalmic viscoelastics and soft tissue fillers.
- Bloomage's functional skin care products feature lotions and facial masks.
Weaknesses
- Bloomage's IPO was on 6 November 2019 with 4,278 employees.
- Bloomage's headquarters is in Jinan, Shandong, China.
- Bloomage's products are limited to hyaluronic acid-based materials.
Opportunities
- Bloomage can expand into functional foods like hyaluronic acid water.
- Bloomage can leverage its medical beauty segment for growth.
- Bloomage can target the cosmetic industry with skin care products.
Threats
- Bloomage faces competition in the hyaluronic acid market from CN companies.
- Bloomage's products are concentrated in the Health Care sector.
- Bloomage's market is limited to CN domestic market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.